Loading

Please wait...

Cayston

Generic Name: aztreonam (inhalation) (AZ tree oh nam)
Brand Names: Cayston
Cayston (aztreonam inhalation) is used to improve breathing symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Includes Cayston side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Cayston

Set your location
for drug prices near you

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Cayston (aztreonam) is an antibiotic that fights severe or life-threatening infection caused by bacteria. Cayston inhalation is used to improve breathing symptoms in people who have cystic fibrosis and a certain bacteria in their lungs. This medication is for use in adults and children who are at least 7 years old. Cayston may also be used for purposes not listed in this medication guide. You should not use Cayston if you are allergic to aztreonam. Before using Cayston, tell your doctor if you are allergic to any type of antibiotic, especially a cephalosporin (Ceftin, Cefzil, Keflex, Omnicef, and others), a penicillin (Amoxil, Augmentin, Bactocill, Bicillin L-a, Dispermox, Dycill, Dynapen, Moxatag, Principen, PC Pen VK, Pen-V, Pfizerpen, Unasyn, and others), or similar antibiotics such as Invanz, Primaxin, or Merrem. Learn more

Cayston Side Effects

Cayston Side Effects

Note: This document contains side effect information about aztreonam. Some of the dosage forms listed on this page may not apply to the brand name Cayston.

In Summary

Common side effects of Cayston include: fever. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to aztreonam: inhalation powder for solution

Other dosage forms:

  • powder for solution, solution

Along with its needed effects, aztreonam (the active ingredient contained in Cayston) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking aztreonam:

More common

  • Chest discomfort
  • cough
  • difficulty with breathing or troubled breathing
  • fever

Less common

  • Noisy breathing
  • shortness of breath
  • tightness in the chest

Some side effects of aztreonam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Abdominal or stomach pain
  • sore throat
  • stuffy nose
  • vomiting

Less common

  • Rash

For Healthcare Professionals

Applies to aztreonam: inhalation powder for reconstitution, injectable powder for injection, intravenous solution

General

Aztreonam (the active ingredient contained in Cayston) for injection was generally well tolerated. The overall incidence of systemic side effects was about 1% to 1.3%.

Respiratory

Aztreonam (the active ingredient contained in Cayston) for inhalation:

Very common (10% or more): Cough (54%), nasal congestion (16%), wheezing (16%)

Common (1% to 10%): Bronchospasm (3%)

Postmarketing reports: Dyspnea

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Wheezing, dyspnea, chest pain, sneezing, nasal congestion

Other

Aztreonam (the active ingredient contained in Cayston) for inhalation:

Very common (10% or more): Pyrexia (13%), pharyngolaryngeal pain (12%)

Common (1% to 10%): Chest discomfort (8%), abdominal pain (7%)

Aztreonam for injection:

Common (1% to 10%): Superinfection (up to 10%)

Uncommon (0.1% to 1%): Less than 1%: Weakness, fever, malaise, flushing

Superinfection has been reported in up to 10% of patients during aztreonam therapy and was usually due to enterococcus or staphylococcus.

Gastrointestinal

Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.

Aztreonam for inhalation:

Common (1% to 10%): Vomiting (6%)

Aztreonam for injection:

Common (1% to 10%): 1% to 1.3%: Nausea, vomiting, diarrhea

Uncommon (0.1% to 1%): Less than 1%: Abdominal cramps, mouth ulcer, altered taste, numb tongue, halitosis

Rare (less than 0.1%): Clostridium difficile associated diarrhea, pseudomembranous colitis, gastrointestinal bleeding

Dermatologic

Toxic epidermal necrolysis associated with aztreonam (the active ingredient contained in Cayston) has been reported in very ill patients on many other medications, making implication of aztreonam difficult.

Aztreonam for inhalation:

Common (1% to 10%): Rash (2%)

Aztreonam for injection:

Common (1% to 10%): Rash (1% to 1.3%)

Uncommon (0.1% to 1%): Less than 1%: Toxic epidermal necrolysis, purpura, erythema multiforme, exfoliative dermatitis, urticaria, petechiae, pruritus, diaphoresis

Local

Aztreonam (the active ingredient contained in Cayston) for injection:

Common (1% to 10%): Discomfort/swelling at the injection site after intramuscular administration (2.4%), phlebitis/thrombophlebitis after intravenous administration (1.9%)

Hypersensitivity

A 57-year-old male developed a widespread maculopapular eruption two hours after receiving aztreonam (the active ingredient contained in Cayston) Corticosteroids and antihistamines were needed to control the reaction which disappeared after 8 days. The patient also showed cross-reactivity to ceftazidime which shares the same side chain as aztreonam.

Aztreonam for inhalation:

Frequency not reported: Allergic reaction (with facial rash, facial swelling, throat tightness)

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Anaphylaxis, angioedema, bronchospasm

Rare (less than 0.1%): Maculopapular eruption (at least 1 case)

Hematologic

A case of myelosuppression associated with aztreonam (the active ingredient contained in Cayston) has been reported, but because many other drugs were administered and because the patient was bacteremic, implication of aztreonam as the causative agent was difficult.

In vitro studies have shown that aztreonam may inhibit ADP-induced platelet aggregation at high concentrations. Clinically, therapeutic doses of aztreonam have not been associated with bleeding problems.

Aztreonam for injection:

Uncommon (0.1% to 1%): Less than 1%: Pancytopenia, neutropenia, thrombocytopenia, anemia, eosinophilia, leukocytosis, thrombocytosis

Frequency not reported: Increased prothrombin time, increased partial thromboplastin time, positive Coombs' test

Hepatic

Aztreonam (the active ingredient contained in Cayston) for injection:

Uncommon (0.1% to 1%): Less than 1%: Hepatitis, jaundice, signs or symptoms of hepatobiliary dysfunction

Frequency not reported: Elevated AST, elevated ALT, elevated alkaline phosphatase

Cardiovascular

Aztreonam (the active ingredient contained in Cayston) for injection:

Uncommon (0.1% to 1%): Hypotension (less than 1%), transient electrocardiogram changes (ventricular bigeminy, premature ventricular contractions; less than 1%)

Nervous system

Aztreonam (the active ingredient contained in Cayston) for injection:

Uncommon (0.1% to 1%): Less than 1%: Seizure, headache, confusion, vertigo, paresthesia, insomnia, dizziness, tinnitus

Musculoskeletal

Aztreonam (the active ingredient contained in Cayston) for inhalation:

Postmarketing reports: Arthralgia, joint swelling

Aztreonam for injection:

Uncommon (0.1% to 1%): Muscular aches (less than 1%)

Renal

Aztreonam (the active ingredient contained in Cayston) for injection:

Rare (less than 0.1%): Acute interstitial nephritis (at least 1 case)

Frequency not reported: Increased serum creatinine

Acute interstitial nephritis associated with aztreonam has been reported in a very ill patient receiving many other medications.

Genitourinary

Aztreonam (the active ingredient contained in Cayston) for injection:

Uncommon (0.1% to 1%): Less than 1%: Vaginal candidiasis, vaginitis, breast tenderness

Ocular

Aztreonam (the active ingredient contained in Cayston) for injection:

Uncommon (0.1% to 1%): Diplopia (less than 1%)

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Cayston (www.drugs.com/cayston.html).